Dendritic cell dysfunction and implications for dendritic cell-based therapy in colorectal cancer
Drugs and Therapy Studies · 2011
DOI: 10.4081/dts.2011.e14 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Therapy Studies, 2011. Verfasst von Michael Vallop Josiassen und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Clinical trials and experimental models indicate that dendritic-cell-based immunotherapy is promising for treatment of different types of cancer. However, dendritic cells (DCs) have strong immune-regulatory capacities and can not only stimulate but also dampen immune responses. It is also well known that the different DC subsets strongly influence the magnitude and quality of adaptive immune responses. In this review, to improve understanding of the DC-based immunotherapy approach, we briefly describe different DC subsets and the differentiation, maturation, and activation of these cells. One form of cancer for which there is a strong need to find, establish, and standardize new, alternative therapies is colorectal cancer. This review discusses some of the factors, including those involved in DC dysfunction, that we believe to be of major influence in DC therapy in colorectal cancer.
Zitieren
APA
Josiassen, M. V., & Paulsson, K. (2011). Dendritic cell dysfunction and implications for dendritic cell-based therapy in colorectal cancer. Drugs and Therapy Studies. https://doi.org/10.4081/dts.2011.e14
Vancouver
Josiassen MV, Paulsson K. Dendritic cell dysfunction and implications for dendritic cell-based therapy in colorectal cancer. Drugs and Therapy Studies. 2011. doi:10.4081/dts.2011.e14
BibTeX
@article{Josiassen2011,
author = {Josiassen, Michael Vallop and Paulsson, Kajsa},
title = {Dendritic cell dysfunction and implications for dendritic cell-based therapy in colorectal cancer},
journal = {Drugs and Therapy Studies},
year = {2011},
doi = {10.4081/dts.2011.e14}
}
EUVIMED